Case report : Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature

Case report : Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature

Hemolytic uremic syndrome (HUS) is a rare thrombotic com-plication characterized by a triad of microangiopathic he-molytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut and liver 2014-01, Vol.8 (1), p.109
Hauptverfasser: Hye Won Lee, Moon Jae Chung, Huap Yong Kang, Heun Choi, Youn Jeong Choi, Kyung Joo Lee, Seung Woo Lee, Seung Hyuk Han, Jin Seok Kim, Si Young Song
Format: Artikel
Sprache:kor
Schlagworte:
Gemcitabine
Hemolytic-uremic syndrome
Pancreatic neoplasms
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hemolytic uremic syndrome (HUS) is a rare thrombotic com-plication characterized by a triad of microangiopathic he-molytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the dis-ease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea. (Gut Liver 2014;8:109-112)
ISSN:1976-2283